Even as most of pharma sees Europe as a mature market ridden with pricing pressures, Teva, by far the world's largest and most successful generics manufacturer, is unabashedly targeting the region as an opportunity.
In a keynote presentation during Euro-Biotech Forum (June 28-30, Paris), Teva CEO Gerard van Odijk, MD, will discuss how the firm plans to balance organic and external growth (through M&A and licensing) as a response to Europe's rapidly changing pharma environment.
For more information, click here!
Here's what you can expect at Euro-Biotech Forum:
- 40+ strategies from pharma heads of R&D, BD, CEOs and corporate VCs - Roche, Bristol-Myers Squibb, Biogen-Idec, Merck Serono, SR One and many more share their in-licensing and strategic alliance criteria!
- 50+ crème of the crop speakers
- 36+ Hand-picked presentations by the industry’s smartest editorial team (IN VIVO, The Pink Sheet and STARTUP)
- 1:1 partnering meetings throughout June 29 and June 30- Identify attendees and plan private meetings in advance.
- 11+ networking opportunities with the most senior level executives in the biopharma business
- Access hundreds of companies, projects and technologies (pre-clinical and clinical stage) which are also linked to Windhover’s Strategic Transactions, IN VIVO articles and Inteleos clinical pipeline links. View the complete history of alliances, financings and M&As.
For more information, click here!
For more information, click here!
New for 2010 - Plenaries covering the following topics:
- Trends in Structured Buyouts
- Strategic Rationale Behind the Most Interesting Deal Structures of the Year
- Project Financing
- Strategic Level Fireside Chats with Special Guests
